Itay & Beyond News
2 articlesBiotech startup Itay & Beyond uses AI analysis of a ‘brain-on-a-chip’ made from stem cells to predict drug efficacy for neuropsychiatric disorders, expedite testing and development
growth-positive
Autism, epilepsy meet next-gen medicine with Israel’s brain chip innovation
Itay and Beyond, an Israeli start-up, is pioneering a new approach to drug discovery for neurological and psychiatric disorders using brain organoids and a 3D brain on a chip technology. This innovative platform, which combines patient-derived brain organoids with advanced AI technology, aims to improve the success rate of translating preclinical studies to clinical trials. The company is focusing on disorders such as autism, epilepsy, and schizophrenia, working in collaboration with medical centers like Hadassah-University Medical Center and Schneider Childrens Medical Center. The technology has attracted interest from pharmaceutical companies due to its potential to revolutionize drug development. Clinical testing for existing drugs could begin within 18 months, highlighting the platforms potential for rapid impact.
Product StagePartners
